The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR) (UG3/UH3 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications for projects that propose to test late-stage (T4) implementation research strategies for optimally and sustainably delivering proven-effective, evidence-based multi--level interventions to reduce or eliminate cardiovascular and/or pulmonary health disparities, and that promote and improve population health in high-burden communities. For the purpose of this FOA, late-stage (T4) implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical and public health practice and community-based settings and maximize the positive impact on population health .
This FOA uses the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism and runs in parallel with a companion FOA ( RFA-HL-20-004 ), which seeks applications for a Research Coordinating Center (RCC). Awards made under this FOA will initially support a milestone-driven needs assessment and planning phase for up to three years, with possible transition to an implementation (UH3) phase of up to four additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase.
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): May 17, 2019; October 1, 2019
RFA-HL-20-003 Expiration Date October 2, 2019
Application budgets may not exceed direct costs of up to $635,000 in Fiscal Year (FY) 2020, and up to $850,000 per year in FY 2021 through FY 2026.